



JUBILANT PHARMOVA

June 26, 2026

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Scrip Code: 530019

Symbol: JUBLPHARMA

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sirs,

In continuation to our earlier communication dated August 2, 2025, regarding the completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the Solid Dosage Manufacturing Facility located at Roorkee, we wish to inform you that Jubilant Generics Limited, a subsidiary of the Company's wholly-owned subsidiary, Jubilant Pharma Limited, has received a tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet.

The aforesaid tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026. Final approval is anticipated upon such patent expiry.

Date and Time of receipt – June 25, 2026; 11:47 am

We request you to take the same on record.

Thanking you,
Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624